About Replay
Replay is a company based in San Diego (United States) founded in 2021 by Ron Weiss, David Knipe, and Lachlan MacKinnon was acquired by LEO Pharma in April 2026. It operates as a HealthTech. Replay has raised $55 million across 2 funding rounds from investors including LEO Pharma, KKR and Gates Foundation. The company has 13 employees as of December 31, 2021. Replay offers products and services including Big DNA Delivery. Replay operates in a competitive market with competitors including BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro, among others.
- Headquarter San Diego, United States
- Employees 13 as on 31 Dec, 2021
- Founders Ron Weiss, David Knipe, Lachlan MacKinnon
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Replay Holdings, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$55 M (USD)
in 2 rounds
-
Latest Funding Round
$1.5 M (USD), Grant
Nov 28, 2022
-
Investors
LEO Pharma
& 8 more
-
Employee Count
13
as on Dec 31, 2021
-
Acquired by
LEO Pharma
(Apr 30, 2026)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Replay
Replay offers a comprehensive portfolio of products and services, including Big DNA Delivery.
Big DNA delivery is developed for disease treatment.
People of Replay
Unlock access to complete
Funding Insights of Replay
Replay has successfully raised a total of $55M across 2 strategic funding rounds. The most recent funding activity was a Grant round of $1.5 million completed in November 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Replay
Replay has secured backing from 9 investors, including institutional and venture fund investors. Prominent investors backing the company include LEO Pharma, KKR and Gates Foundation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Multiple sectors are invested in by this private equity firm.
|
Locked | Locked | Locked | |
|
Venture capital investments are made in transformative biotech companies by OMX Ventures.
|
Locked | Locked | Locked | |
|
Early-stage startups are invested in by Artis Ventures.
|
Locked | Locked | Locked |
Investor details for Replay
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Replay
Investment portfolio details for Replay
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Replay
Detailed financials for Replay
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Replay Comparisons
Peer comparison for Replay
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Replay
Replay operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| Locked | Locked | Locked |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| Locked | Locked | Locked |
RNA interference-based therapeutics are developed for multiple disorders.
|
|
| Locked | Locked | Locked |
A biopharmaceutical company accelerating innovative mental health treatments.
|
|
| Locked | Locked | Locked |
An AI-enabled platform is developed for infectious disease treatment.
|
|
| Locked | Locked | Locked |
Therapeutics for rare and ultra-rare metabolic diseases are developed.
|
Detailed competitors of Replay
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Replay
Complete news archive for Replay
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Replay
Replay was founded in 2021 and raised its 1st funding round 1 year after it was founded.
Replay is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Lachlan MacKinnon is the current CEO of Replay. They have also founded this company.
Replay is a funded company, having raised a total of $55M across 2 funding rounds to date.
As of Dec 31, 2021, the latest employee count at Replay is 13.
Replay is engaged in developing big DNA delivery solutions for treating monogenic and polygenic diseases through gene therapy. The company specializes in delivering 150kb DNA using HSV technology. Their efforts are centered in the biotechnology sector, aiming to address complex genetic disorders with innovative therapeutic approaches.
Replay's top competitors include Spark Therapeutics, BridgeBio and Forge Biologics.
Replay offers Big DNA Delivery.
Replay has 9 investors. Key investors include LEO Pharma, KKR, Gates Foundation, Salt Mobile, and OMX Ventures.